Annual report pursuant to Section 13 and 15(d)

Note 3 - Revenue From Contracts With Customers (Tables)

v3.22.1
Note 3 - Revenue From Contracts With Customers (Tables)
12 Months Ended
Dec. 31, 2021
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Years Ended

December 31,

 
   

2021

   

2020

 

Royalty revenue:

               

Tc99m tilmanocept - Europe

  $     $ 7,995  
                 

License revenue:

               

Tc99m tilmanocept - Europe

  $ 45,615     $ 110,730  
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
   

Year Ended December 31,

 
   

2021

   

2020

 

Total deferred revenue, beginning of period

  $ 700,000     $ 700,000  

Revenue deferred related to sublicense

          160,000  

Refund of deferred revenue related to sublicense

          (160,000

)

Revenue recognized from satisfaction of performance obligations

           

Total deferred revenue, end of period

  $ 700,000     $ 700,000